Public annual accounts

Danis Pharma financials

Name: Danis Pharma financials
Creator: Upswitch
License: https://www.upswitch.app/terms-and-conditions

A multi-period view of the public annual-account figures reported for Danis Pharma, with comparable measures and links to available source documents.

Company overview

Registry number

0465345721

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 28, 2026

Financial evidence

Latest movements for Danis Pharma

2025 versus 2024

Operating line: €113,647
EBITDA: €104,453
Total assets: €866,100
Equity: €784,088

EBITDA margin +91.9% · Equity ratio +90.5%

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO

Fiscal year	Gross margin	EBITDA	Total assets	Equity	Filing
202530 Jun 2025	€113,647	€104,453	€866,100	€784,088	-
202430 Jun 2024	€124,638	€117,496	€819,478	€712,381	-

Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report